NYSE:CBM - Cambrex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$40.17 -1.47 (-3.53 %)
(As of 12/18/2018 06:27 AM ET)
Previous Close$41.64
Today's Range$39.90 - $41.8850
52-Week Range$39.90 - $69.43
Volume535,655 shs
Average Volume353,822 shs
Market Capitalization$1.40 billion
P/E Ratio12.67
Dividend YieldN/A
Beta2.36
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNYSE:CBM
Previous Symbol
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity Ratio0.49
Current Ratio4.54
Quick Ratio3.41

Price-To-Earnings

Trailing P/E Ratio12.67
Forward P/E Ratio14.50
P/E Growth1.5

Sales & Book Value

Annual Sales$534.46 million
Price / Sales2.52
Cash Flow$4.0658 per share
Price / Cash Flow9.88
Book Value$16.62 per share
Price / Book2.42

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins22.67%
Return on Equity22.20%
Return on Assets14.86%

Miscellaneous

Employees1,228
Outstanding Shares33,560,000
Market Cap$1.40 billion
OptionableOptionable

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) announced its earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.59 by $0.10. The biotechnology company had revenue of $104.62 million for the quarter, compared to the consensus estimate of $122.04 million. Cambrex had a return on equity of 22.20% and a net margin of 22.67%. The company's revenue was down 7.1% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.79.

What price target have analysts set for CBM?

5 Wall Street analysts have issued 12-month price targets for Cambrex's stock. Their predictions range from $63.00 to $75.50. On average, they expect Cambrex's stock price to reach $69.25 in the next year. This suggests a possible upside of 72.4% from the stock's current price. View Analyst Price Targets for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Has Cambrex been receiving favorable news coverage?

News coverage about CBM stock has trended negative recently, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near future.

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 52)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. James G. Farrell, VP & Corp. Controller (Age 51)

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.23%), Vanguard Group Inc. (9.78%), Vanguard Group Inc (9.78%), William Blair Investment Management LLC (7.54%), Bank of New York Mellon Corp (4.51%) and Dimensional Fund Advisors LP (4.22%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

Which institutional investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Wells Fargo & Company MN, Tributary Capital Management LLC, Panagora Asset Management Inc., Janus Henderson Group PLC, Prudential Financial Inc., Rice Hall James & Associates LLC and Cambiar Investors LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

Which institutional investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Acadian Asset Management LLC, William Blair Investment Management LLC, Castleark Management LLC, Clearbridge Investments LLC, Copper Rock Capital Partners LLC, Oak Ridge Investments LLC and LSV Asset Management. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $40.17.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.40 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

What is Cambrex's official website?

The official website for Cambrex is http://www.cambrex.com.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  420
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel